Filing Flows › Guardant Health (GH) › Biopharma and data revenue
Guardant Health (GH) Biopharma and data revenue by quarter
Guardant Health's Biopharma and data revenue was $59.0M in Q3 2026 (third quarter 2026), -3% from Q2 2026. Over the last 7 quarters it ranged from $45.4M (Q1 2025) to $60.9M (Q2 2026).
| Quarter | Biopharma and data revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $59.0M | -3% | +8% |
| Q2 2026 | $60.9M | +15% | +9% |
| Q1 2026 | $53.0M | -2% | +17% |
| Q4 2025 | $54.0M | -1% | — |
| Q3 2025 | $54.7M | -2% | — |
| Q2 2025 | $56.0M | +23% | — |
| Q1 2025 | $45.4M | — | — |
Q3 2026 at a glance
Guardant Health, Q3 2026: revenue $361M (+36% year over year), operating margin -36.8%, net loss $124M, operating cash flow −$23.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Guardant Health's Biopharma and data revenue?
Guardant Health's Biopharma and data revenue was $59.0M in Q3 2026 (third quarter 2026), -3% from Q2 2026.
How has Guardant Health's Biopharma and data revenue changed?
Over the last 7 quarters it ranged from $45.4M (Q1 2025) to $60.9M (Q2 2026).